Molnupiravir was associated with a decreased the risk of hospitalization from Covid-19 by only 30%, compared to a reduction of almost 90% with Pfizer's PAXLOVID. The FDA advisory committee also limited its use in non-pregnant adults because of their concerns about the potential risk of mutations in human DNA.

Executives from major airlines, retailers and manufacturers – plus at least one NFL owner – talked about potential ways to show they opposed the controversial legislation, including by halting donations to politicians who support the bills and even delaying investments in states that pass the restrictive measures